The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. That is as true in the United States as anywhere else in the country. Read against the United States market, ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. For anyone weighing options in the United States, the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations.
In the United States the same rule applies: the useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. That holds in the United States as it does everywhere: advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. Patients researching the United States providers run into this constantly. A driver is mandatory, and across six sessions in three weeks that means arranging somebody else's time repeatedly rather than once. The United States listings on this page are organised so that this is checkable rather than assumed. Taken at face value, search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier.
Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
What happens after the first course of treatment
Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. Nothing about the United States changes that. Whether a programme is led by someone trained in sedation or someone trained in mood disorders changes what gets emphasised and what gets assumed. It is worth carrying that into every conversation with a the United States provider. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. It is the first thing to establish about any the United States programme. Anyone comparing the United States programmes will find this decisive: a consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all.
Every the United States programme is operating inside the same clinical framework, which runs as follows. Comparing clinics is difficult because the variables that matter are not the ones displayed on the website. Two facilities can charge similar prices and offer materially different care. The questions that separate them are who is physically present during the session and what their credential is, whether monitoring is continuous or intermittent, how the dose is determined and whether it is adjusted between sessions, what the plan is if a person does not respond after the induction course, whether psychiatric care is coordinated with an existing prescriber, and what integration support exists. Those answers can be obtained in one phone call, and the willingness to give them plainly is itself informative.
A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. Applied to the United States, the point is this: the induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals.
How to decide without guessing
An anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it. Patients researching the United States providers run into this constantly. Programmes differ enormously in how seriously they take the therapeutic work around the infusion, ranging from employed therapists to a photocopied worksheet. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Anyone comparing the United States programmes will find this decisive: a programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed.
None of the United States detail on this page makes sense without the clinical context behind it. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
That holds in the United States as it does everywhere: using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. If the neuroplasticity hypothesis is right, what happens between sessions is not an optional extra but part of how the treatment is meant to function. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. It is the first thing to establish about any the United States programme. Read against the United States market, weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions.
Where the evidence is strong and where it thins out
Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. For anyone weighing options in the United States, resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting. The relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring. That is as true in the United States as anywhere else in the country.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
Applied to the United States, the point is this: preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. It is worth carrying that into every conversation with a the United States provider. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. In the United States the same rule applies: the open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. Distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal.
The practical checklist, written as prose
Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. The United States listings on this page are organised so that this is checkable rather than assumed. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. Nothing about the United States changes that. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. The United States listings on this page are organised so that this is checkable rather than assumed.
The setting is not incidental decoration. Trial protocols were run in monitored medical environments, and the structural elements of those environments are part of what makes the treatment defensible: a clinician credentialed to manage sedation present in the building, continuous monitoring of blood pressure, heart rate and oxygen saturation, resuscitation equipment available, and a defined plan for what happens if someone becomes acutely distressed. A comfortable recliner and dim lighting are pleasant. They are not a substitute for any of the preceding items, and a tour that emphasises the former while being vague about the latter has answered a question you did not ask.
For anyone weighing options in the United States, appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. The reason vital signs are tracked throughout is unglamorous: ketamine raises blood pressure and heart rate transiently, and someone needs to be watching when it does. It is the first thing to establish about any the United States programme. Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. That holds in the United States as it does everywhere: remote consultation paired with on-site administration is a sensible hybrid, and several programmes now structure themselves that way for travelling patients. A standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. That is as true in the United States as anywhere else in the country. The clinicians running these programmes come from anaesthesiology, psychiatry, emergency medicine and pain management, and the route shapes how the treatment is framed. Patients researching the United States providers run into this constantly.
Cost, coverage and the numbers nobody posts
The reason vital signs are tracked throughout is unglamorous: ketamine raises blood pressure and heart rate transiently, and someone needs to be watching when it does. Nothing about the United States changes that. Anyone comparing the United States programmes will find this decisive: provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. Applied to the United States, the point is this: a consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all.
Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. It is worth carrying that into every conversation with a the United States provider. In the United States the same rule applies: six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. An anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it.
What to take from all of this
A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. The logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. Read against the United States market, uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.